{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:56:56Z","timestamp":1781647016494,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Preclinically, radiopharmaceuticals are currently mainly evaluated in two-dimensional (2D) cell models, which lack clinical features that are relevant for accurate evaluation of targeted radionuclide therapy (TRT) responses. The development of three-dimensional (3D) cell models in the last years offers opportunities to overcome at least parts of the limitations of 2D cell models, but such 3D cell models are currently only rarely used in nuclear medicine research. Moreover, the comparison between 2D and 3D cell models, aimed at demonstrating the potential added value of 3D cell models, is even more scarce. To fill this gap and promote the use of more clinically relevant 3D cell models in nuclear medicine research, we performed such a comparative study. For this, we developed and evaluated 3D cell models derived from the prostate-specific membrane antigen (PSMA)-expressing human cancer cell lines LNCaP and PC3-PIP, by culturing these cells in anti-adhesive round bottom plates (\u201cbio-spheroids\u201d) or by culturing LNCaP cells in Matrigel (MG) or Noviogel-P5K (NG) domes (\u201dMG-spheroids\u201d or \u201cNG-spheroids\u201d). Hereafter, PSMA expression levels and [\n                      <jats:sup>111<\/jats:sup>\n                      In]In-PSMA-I&amp;T uptake were determined and compared between 3D and 2D cell models. Additionally, we assessed cell viability of 3D- versus 2D-cultured cells after external beam radiation therapy (EBRT) and PSMA-TRT using [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No significant differences in viability were observed between bio-spheroids versus 2D cell models after EBRT and PSMA-TRT, neither in LNCaP nor in PC3-PIP cells. In contrast, LNCaP MG-spheroids had a significantly better response to PSMA-TRT in comparison to the 2D-cultured cells. This was despite a lower PSMA expression level and lower [\n                      <jats:sup>111<\/jats:sup>\n                      In]In-PSMA-I&amp;T uptake in the MG-spheroids. Importantly, no significant difference in radiosensitivity was observed between these MG-spheroids and the 2D cell model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite lower PSMA expression levels and lower radiopharmaceutical uptake in LNCaP MG-spheroids, and albeit similar radiosensitivity, PSMA-TRT induced a stronger reduction in viability in the MG-spheroids in comparison to the 2D-cultured cells. In contrast, no differences were observed in PSMA-TRT efficacy between bio-spheroids and the 2D cell model. The aforementioned leads to the hypothesis that biological factors important for TRT, e.g. cross-radiation and radiopharmaceutical retention within the 3D cell structure, are better represented in MG-spheroids where cell-cell interactions are already formed prior to radiopharmaceutical incubation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01393-0","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:25:59Z","timestamp":1775193959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D"],"prefix":"10.1186","volume":"16","author":[{"given":"Maria J.","family":"Klomp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun E.","family":"Erkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske M.","family":"van Weerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-6901","authenticated-orcid":false,"given":"Simone U.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera(\u00ae): the first FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019;12(3):114. https:\/\/doi.org\/10.3390\/ph12030114.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1393_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-Approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15(10):1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1393_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14311","author":"M Hassan","year":"2023","unstructured":"Hassan M, Bokhari TH, Lodhi NA, Khosa MK, Usman M. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes. Chem Biol Drug Des. 2023;102(5):1276\u20131292. https:\/\/doi.org\/10.1111\/cbdd.14311.","journal-title":"Chem Biol Drug Des"},{"key":"1393_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06316-y","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller C, van der Meulen NP, Schibli R. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. Eur J Nucl Med Mol Imaging. 2023;50(11):3181\u20133184. https:\/\/doi.org\/10.1007\/s00259-023-06316-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1393_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050674","author":"TST Damiana","year":"2021","unstructured":"Damiana TST, Dalm SU. Combination therapy, a promising approach to enhance the efficacy of radionuclide and targeted radionuclide therapy of prostate and breast cancer. Pharmaceutics. 2021;13(5):674. https:\/\/doi.org\/10.3390\/pharmaceutics13050674.","journal-title":"Pharmaceutics"},{"key":"1393_CR6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248062","author":"TG Chan","year":"2020","unstructured":"Chan TG, O\u2019Neill E, Habjan C, Cornelissen B. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020;61(11):1544\u20131552. https:\/\/doi.org\/10.2967\/jnumed.120.248062.","journal-title":"J Nucl Med"},{"key":"1393_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4332","author":"SC Kleinendorst","year":"2022","unstructured":"Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S. Combining targeted radionuclide therapy and immune checkpoint Inhibition for cancer treatment. Clin Cancer Res. 2022;28(17):3652\u20133657. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4332.","journal-title":"Clin Cancer Res"},{"key":"1393_CR8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.63743","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, Ibbs M, Bli\u017aniak R, \u0141uczewski \u0141, Lamperska K. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(4):910\u2013919. https:\/\/doi.org\/10.5114\/aoms.2016.63743.","journal-title":"Arch Med Sci"},{"key":"1393_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.04.001","author":"S Pozzi","year":"2021","unstructured":"Pozzi S, Scomparin A, Israeli Dangoor S, Rodriguez Ajamil D, Ofek P, Neufeld L, Krivitsky A, Vaskovich-Koubi D, Kleiner R, Dey P, Koshrovski-Michael S, Reisman N, Satchi-Fainaro R. Meet me halfway: are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development? Adv Drug Deliv Rev. 2021;175:113760. https:\/\/doi.org\/10.1016\/j.addr.2021.04.001.","journal-title":"Adv Drug Deliv Rev"},{"key":"1393_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00215","author":"D Brady","year":"2013","unstructured":"Brady D, O\u2019Sullivan JM, Prise KM. What is the role of the bystander response in radionuclide therapies? Front Oncol. 2013;3:215. https:\/\/doi.org\/10.3389\/fonc.2013.00215.","journal-title":"Front Oncol"},{"key":"1393_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07123-3","author":"L Bokhout","year":"2025","unstructured":"Bokhout L, Campeiro JD, Dalm SU. Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics. Eur J Nucl Med Mol Imaging. 2025;52(9):3291\u20133311. https:\/\/doi.org\/10.1007\/s00259-025-07123-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1393_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1087057117696795","author":"Y Fang","year":"2017","unstructured":"Fang Y, Eglen RM. Three-Dimensional cell cultures in drug discovery and development. SLAS Discov. 2017;22(5):456\u2013472. https:\/\/doi.org\/10.1177\/1087057117696795.","journal-title":"SLAS Discov"},{"key":"1393_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02021-y","author":"F Vakhshiteh","year":"2023","unstructured":"Vakhshiteh F, Bagheri Z, Soleimani M, Ahvaraki A, Pournemat P, Alavi SE, Madjd Z. Heterotypic tumor spheroids: a platform for nanomedicine evaluation. J Nanobiotechnol. 2023;21(1):249. https:\/\/doi.org\/10.1186\/s12951-023-02021-y.","journal-title":"J Nanobiotechnol"},{"key":"1393_CR14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25266","author":"NK Purohit","year":"2018","unstructured":"Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM. Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget. 2018;9(37):24693\u201324706. https:\/\/doi.org\/10.18632\/oncotarget.25266.","journal-title":"Oncotarget"},{"key":"1393_CR15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265997","author":"FN Njotu","year":"2024","unstructured":"Njotu FN, Ketchemen JP, Tikum AF, Babeker H, Gray BD, Pak KY, Uppalapati M, Fonge H. Efficacy of [(67)Cu]Cu-EB-TATE theranostic against somatostatin receptor Subtype-2-Positive neuroendocrine tumors. J Nucl Med. 2024;65(4):533\u2013539. https:\/\/doi.org\/10.2967\/jnumed.123.265997.","journal-title":"J Nucl Med"},{"key":"1393_CR16","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4888","author":"S Lundsten","year":"2019","unstructured":"Lundsten S, Spiegelberg D, Stenerl\u00f6w B, Nestor M. The HSP90 inhibitor onalespib potentiates 177Lu\u2013DOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019;55(6):1287\u20131295. https:\/\/doi.org\/10.3892\/ijo.2019.4888.","journal-title":"Int J Oncol"},{"key":"1393_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094815","author":"VY Stenberg","year":"2021","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland \u00d8S, Juzeniene A. Evaluation of the PSMA-Binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22(9):4815. https:\/\/doi.org\/10.3390\/ijms22094815.","journal-title":"Int J Mol Sci"},{"key":"1393_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10266","author":"D Salerno","year":"2022","unstructured":"Salerno D, Howe A, Bhatavdekar O, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, Gabrielson KL, Sofou S. Two diverse carriers are better than one: A case study in \u03b1-particle therapy for prostate specific membrane antigen-expressing prostate cancers. Bioeng Transl Med. 2022;7(2):e10266. https:\/\/doi.org\/10.1002\/btm2.10266.","journal-title":"Bioeng Transl Med"},{"key":"1393_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20502","author":"J Wang","year":"2006","unstructured":"Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, Li Y. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate. 2006;66(16):1753\u20131767. https:\/\/doi.org\/10.1002\/pros.20502.","journal-title":"Prostate"},{"key":"1393_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242317015","author":"J Raitanen","year":"2023","unstructured":"Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D, Mitterhauser M. Radiobiological assessment of targeted radionuclide therapy with [(177)Lu]Lu-PSMA-I&T in 2D vs. 3D cell culture models. Int J Mol Sci. 2023;24(23):17015. https:\/\/doi.org\/10.3390\/ijms242317015.","journal-title":"Int J Mol Sci"},{"key":"1393_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-022-00181-0","author":"EL Hooijman","year":"2022","unstructured":"Hooijman EL, Ntihabose CM, Reuvers TGA, Nonnekens J, Aalbersberg EA, van de Merbel J, Huijmans JE, Koolen SLW, Hendrikx J, de Blois E. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC\/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA. EJNMMI Radiopharm Chem. 2022;7(1):29. https:\/\/doi.org\/10.1186\/s41181-022-00181-0.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1393_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1054-4","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30(2):312\u2013315. https:\/\/doi.org\/10.1007\/s00259-002-1054-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1393_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-020-0199-8","author":"EA Aisenbrey","year":"2020","unstructured":"Aisenbrey EA, Murphy WL. Synthetic alternatives to matrigel. Nat Rev Mater. 2020;5(7):539\u2013551. https:\/\/doi.org\/10.1038\/s41578-020-0199-8.","journal-title":"Nat Rev Mater"},{"key":"1393_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101377","author":"A Van Hemelryk","year":"2023","unstructured":"Van Hemelryk A, Erkens-Schulze S, Lim L, de Ridder CMA, Stuurman DC, Jenster GW, van Royen ME, van Weerden WM. Viability analysis and High-Content Live-Cell imaging for drug testing in prostate cancer Xenograft-Derived organoids. Cells. 2023;12(10):1377. https:\/\/doi.org\/10.3390\/cells12101377.","journal-title":"Cells"},{"key":"1393_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111572","author":"A Van Hemelryk","year":"2021","unstructured":"Van Hemelryk A, Mout L, Erkens-Schulze S, French PJ, van Weerden WM, van Royen ME. Modeling prostate cancer treatment responses in the organoid era: 3D environment impacts drug testing. Biomolecules. 2021;11(11):1572. https:\/\/doi.org\/10.3390\/biom11111572.","journal-title":"Biomolecules"},{"key":"1393_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030360","author":"J Raitanen","year":"2023","unstructured":"Raitanen J, Barta B, Hacker M, Georg D, Balber T, Mitterhauser M. Comparison of radiation response between 2D and 3D cell culture models of different human cancer cell lines. Cells. 2023;12(3):360. https:\/\/doi.org\/10.3390\/cells12030360.","journal-title":"Cells"},{"key":"1393_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3319-0","author":"S Riffle","year":"2017","unstructured":"Riffle S, Pandey RN, Albert M, Hegde RS. Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer. 2017;17(1):338. https:\/\/doi.org\/10.1186\/s12885-017-3319-0.","journal-title":"BMC Cancer"},{"issue":"3","key":"1393_CR28","first-page":"1116","volume":"12","author":"E Jouberton","year":"2022","unstructured":"Jouberton E, Voissiere A, Penault-Llorca F, Cachin F, Miot-Noirault E. Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs. Am J Cancer Res. 2022;12(3):1116\u20131128.","journal-title":"Am J Cancer Res."},{"key":"1393_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06144-0","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, van Lith SAM, Mehra N, Nagarajah J, Heskamp S, Westdorp H. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50(7):1906\u20131918. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01393-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:26:14Z","timestamp":1781645174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01393-0","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}